| Size | Price | |
|---|---|---|
| 50mg | ||
| 100mg | ||
| 250mg |
| ln Vitro |
NCI-N87 and AGS cell viability is lowered by thioridazine (0.01-100 μM; 48 h) in a concentration-dependent manner [2]. Cell viability of endometrial cancer cells (HEC-1-A and KLE) and cervical cancer cells (HeLa, Caski, and C33A) is decreased by thioridazine (15 μM; 24 hours) [4]. Through both the mitochondrial pathway and the mitochondrial apoptotic pathway, thioridazine (1–15 μM; 24-48 h) causes the death of gastric cancer cells [2]. In cervical and endometrial cancer cells, thioridazine (15 μM; 24 hours) promotes G1 cell cycle arrest and interferes with the PI3K/Akt pathway to regulate cell cycle progression [4]. Acinetobacter baumannii strains that are both multidrug resistant and susceptible to antibiotics cannot develop when thioridazine is used [3].
|
|---|---|
| ln Vivo |
Tumor-bearing mice's survival is extended when thioridazine (25 mg/kg; intraperitoneally every 3 days for 3 weeks) is administered, and the amount of pluripotent embryonal carcinoma cells (ECs) inside the tumors is decreased [5]. Subcutaneous injection of thioridazine (1.0-5.0 mg/kg) lowers oral habits and inhibits repetitive head bobbing selectively [1].
|
| Cell Assay |
Cell viability assay[1]
Cell Types: NCI-N87 and AGS cells. Tested Concentrations: 0.01, 0.1, 0.5, 1, 5, 10, 20, 50, 100 μM. Incubation Duration: 48 hrs (hours). Experimental Results: demonstrated cytotoxicity to gastric cancer cells. Western Blot Analysis[1] Cell Types: NCI-N87 and AGS Cell Tested Concentrations: 1, 5, 10, 15 μM. Incubation Duration: 24, 48 hrs (hours). Experimental Results: Down-regulation of caspase-9, caspase-8 and caspase-3 precursor proteins. |
| Animal Protocol |
Animal/Disease Models: Nude mice and Rag2KO mice were injected with iPS cells or NT2D1 cells [5].
Doses: 25 mg/kg. Route of Administration: IP every 3 days for 3 weeks. Experimental Results: The number of OCT4-expressing cells in malignant teratocarcinoma was diminished and the survival period of tumor-bearing mice was prolonged. Has no effect on fertility. |
| References |
[1]. Tschanz JT, et, al. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy. Pharmacol Biochem Behav. 1988 Nov;31(3):519-22.
[2]. Mu J, et, al. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep. 2014 May;31(5):2107-14. [3]. Kang S, et, al. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012 Sep;17(9):989-97. [4]. Loehr AR, et, al. Targeting Cancer Stem Cells with Differentiation Agents as an Alternative to Genotoxic Chemotherapy for the Treatment of Malignant Testicular Germ Cell Tumors. Cancers (Basel). 2021 Apr 23;13(9):2045. |
| Molecular Formula |
C21H26N2S2
|
|---|---|
| Molecular Weight |
370.573
|
| Exact Mass |
370.15374
|
| CAS # |
50-52-2
|
| Related CAS # |
Thioridazine hydrochloride;130-61-0;Thioridazine-d3 hydrochloride;1189928-36-6
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
|
| Synonyms |
Thioridazine Melleril Mellaril
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6985 mL | 13.4927 mL | 26.9855 mL | |
| 5 mM | 0.5397 mL | 2.6985 mL | 5.3971 mL | |
| 10 mM | 0.2699 mL | 1.3493 mL | 2.6985 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
